Beneficial effects of statins after percutaneous coronary intervention

European Journal of Cardiovascular Prevention and Rehabilitation

Volumn 16, Issue 4, 2009, Pages 445-450

  Zhang, Zhi Jiang ^a   Marroquin, Oscar C ^d   Weissfeld, Joel L ^b   Stone, Roslyn A ^c   Mulukutla, Suresh R ^d   Williams, David O ^e   Selzer, Faith ^b   Kip, Kevin E ^e  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Mortality; Propensity score; Repeat revascularization; Stent

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NITRATE; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG EFFECT; FEMALE; FOLLOW UP; HEART PROTECTION; HOSPITAL DISCHARGE; HUMAN; IMPLANTATION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVASCULARIZATION; RISK FACTOR; STENT; SURVIVOR;

EID: 70349210562     PISSN: 17418267     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32832a4e3b     Document Type: Article

References (27)

1. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389.
2. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
3. Strandberg TE, Pyorala K, Cook TJ, Wilhelmsen L, Faergeman O, Thorgeirsson G, et al. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet 2004; 364:771-777.
4. Hong YJ, Jeong MH, Hyun DW, Hur SH, Kim KB, Kim W, et al. Prognostic significance of simvastatin therapy in patients with ischemic heart failure who underwent percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 95:619-622.
5. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, Topol EJ, et al. Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002; 105: 691-696.
6. Yamawaki T, Yamada A, Fukumoto Y, Kishi T, Sobashima A, Kuwata K, et al. Statin therapy may prevent restenosis after successful coronary intervention, independent of lipid-lowering effect and CRP level. Fukuoka Igaku Zasshi 2007; 98:260-269.
7. Mood GR, Bavry AA, Roukoz H, Bhatt DL. Meta-analysis of the role of statin therapy in reducing myocardial infarction following elective percutaneous coronary intervention. Am J Cardiol 2007; 100:919-923.
8. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
9. Rosenbaum PR, Rubin DB. Reducing bias in observational studies. J Am Stat Assoc 1984; 79:516-524.
10. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
11. Kasai T, Miyauchi K, Kurata T, Satoh H, Ohta H, Tanimoto K, et al. Long-term (11-year) statin therapy following percutaneous coronary intervention improves clinical outcome and is not associated with increased malignancy. Int J Cardiol 2007; 114:210-217.
12. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the Fluvastatin Angiographic Restenosis (FLARE) trial. Eur Heart J 1999; 20 :58-69.
13. Weintraub WS, Boccuzzi SJ, Klein JL, Kosinski AS, King SB 3rd, Ivanhoe R, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group. N Engl J Med 1994; 331:1331-1337.
14. Bertrand ME, McFadden EP, Fruchart JC, Van Belle E, Commeau P, Grollier G, et al. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of restenosis by elisor after transluminal coronary angioplasty. J Am Coll Cardiol 1997; 30:863-869.
15. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215-3222.
16. Tailor A, Lefer DJ, Granger DN. HMG-CoA reductase inhibitor attenuates platelet adhesion in intestinal venules of hypercholesterolemic mice. Am J Physiol Heart Circu Physiol 2004; 286:H1402-H1407.
17. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92 :3172-3177.
18. Guven GS, Atalar E, Yavuz B, Beyazit Y, Kekilli M, Kilicarslan A, et al. Simvastatin treatment improves endothelial function and increases fibrinolysis in patients with hypercholestrolemia. J Natl Med Assoc 2006; 98 :627-630.
19. Crisby M, Nordin-Fredriksson G, Shah P, Yano J, Zhu J, Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001; 103:926-933.
20. Sattar N, Murray HM, McConnachie A, Blauw GJ, Bollen ELEM, Buckley BM, et al. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2007; 115:981-989.
21. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
22. Baetta R, Donetti E, Comparato C, Calore M, Rossi A, Teruzzi C, et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res 1997; 36:115-121.
23. Guijarro C, Blanco-Colio LM, Ortego M, Alonso C, Ortiz A, Plaza JJ, et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83:490-500.
24. Corsini A, Pazzucconi F, Pfister P, Paoletti R, Sirtori CR. Inhibitor of proliferation of arterial smooth-muscle cells by fluvastatin. Lancet 1996; 348:1584.
25. Buemi M, Allegra A, Senatore M, Marino D, Medici MA, Aloisi C, et al. Pro-apoptotic effect of fluvastatin on human smooth muscle cells. Eur J Pharmacol 1999; 370:201-203.
26. Sahni R, Maniet AR, Voci G, Banka VS. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121 (6 Pt 1):1600-1608.
27. Schartl M, Bocksch W, Koschyk DH, Voelker W, Karsch KR, Kreuzer J, et al. Use of intravascular ultrasound to compare effects of different strategies of lipid-lowering therapy on plaque volume and composition in patients with coronary artery disease. Circulation 2001; 104:387-392.